Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 Combinations in Advanced Cancer
NCT02900664Phase 1Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 9
01
Overview
Phase 1, open-label trial of spartalizumab in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (23 arms), sponsored by Novartis. Primary endpoints: Adverse Events at 1 year, Laboratory parameters and vital signs at 1 year and 5 more. Started Aug 2016; status: completed.
02
Drugs
spartalizumab
03
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02900664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900664.